BioSpace News Archive

FDA

RICOH MEG Receives FDA 510(k) Clearance

RICOH MEG, Ricoh’s magnetoencephalography system, is a noninvasive way to detect faint signals within the brain.

November 30, 2017
·
1 min read
Biotech Bay

Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4

Analyst and Investor Day will be an opportunity to provide updates on our clinical and early stage pipeline, including the newly acquired gene therapy programs, as well as a commercial overview.

November 30, 2017
·
2 min read
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR by Par Pharmaceutical

The launch of the 5 and 40 mg strengths complements the 10, 15, 20, 25, 30 and 35 mg strengths of generic Focalin XR previously launched and marketed by Par.

November 30, 2017
·
10 min read
Business

Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive VP Finance and a Member of the Management Board (Vorstand)

Epigenomics announced today that the Supervisory Board appointed Albert Weber Executive VP of Finance effective January 1, 2018.

November 30, 2017
·
2 min read
Business

Sales of Olainfarm in Nine Months Reach 90.4M Euros

Olainfarm just had its best third quarter in terms of sales.

November 30, 2017
·
5 min read
Business

Orchard Therapeutics Announces Expansion of Technical Operations in California

Orchard today announced the opening of a second facility for technical operations in the San Francisco Bay Area.

November 30, 2017
·
3 min read
Biotech Beach

TearLab Launches Registered Direct Offering

The Company plans to use the proceeds of this offering for general corporate purposes.

November 30, 2017
·
4 min read
Scythian Biosciences Completes Sale of Go Green

In addition to the cash compensation received, 27,000 common shares of Scythian are being returned to treasury for cancellation.

November 30, 2017
·
3 min read
Verona Pharma: PDMR Dealing

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

November 30, 2017
·
1 min read
Drug Development

Final Patient Completes Treatment in Innovation Pharmaceuticals Phase IIb Study of Oral Prurisol for Psoriasis

Prurisol is being developed as a novel, nonbiologic, oral psoriasis drug candidate.

November 30, 2017
·
8 min read